Roche To Work On Reversing English Funding Rejection For SMA Drug
But Tecentriq Gets NICE Thumbs Up For NSCLC
Evrysdi could follow Spinraza and Zolgensma to become the third treatment for spinal muscular atrophy available on England’s National Health Service if Roche can agree on a lower price for the drug.
